Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids in people aged 12 and over [ID6377] Draft guidance Technology appraisal guidance 10 January 2025 Cladribine for ...

We’ve issued final draft guidance recommending a new once-a-day tablet that is set to benefit around 1,100 people with a type ...

Cost-effectiveness thresholds play a vital role in healthcare decision-making, helping to ensure that NHS resources are used ...

Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer TA1021 4 December 2024 4 December 2024 ...

NICE is proposing changes to its routing criteria for Highly Specialised Technologies (HST) to ensure more consistent, ...

Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments TA1023 11 December 2024 11 December 2024 ...

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to ...

Anhydrous sodium thiosulfate, also known as Pedmarqsi and made by Norgine, is recommended in final draft guidance for preventing hearing loss caused by cisplatin chemotherapy in children from the ages ...

Tirzepatide's gastrointestinal adverse effects could lead to dehydration and in turn a deterioration in renal function including acute renal failure. Older people and some other groups of people may ...

For further information on the guideline development process, please see how we develop NICE guidelines ...

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.